Spanish fair surpasses expectations


Granada – “We’ve broken all records.” This was Jose Luis Jarcano’s (Genoma Espana) conclusion after the end of the 4th BioSpain in Granada, Spain’s 3rd largest bio­tech cluster. “BioSpain 2008 has attracted more exhibitors, professionals and international delegates than any of its predecessors,” said Jose Maria Fernendez, President of the co-organising Spanish Association of Bioenterprises (ASEBIO). “The numbers demonstrate that the sector is in good health.”
The three-day event surpassed the BioSpain 2006 held in Madrid. Many of the 162 exhibitors spoke of a “tremendous leap in quality”, because practically the entire domestic sector took part. A high-ranking scientific congress entitled “Biotech 2008”, organised by Spanish biotech society SEBIOT, spanned a wide spectrum of issues: from bio­chemical engineering to agri-food, industrial biotech to microbial genomics, biocatalysis to bioinformatics. A partnerning forum organised by the EBD group counted 1,000 face-to-face meetings. In addition, 5 out of the 28 biotechs presenting to international investors were rewarded at the end of BioSpain’s finance forum: SpinX (Switzerland), CelleriX (Spain), Alfama (Portugal), Amsterdam Molecular Therapies (Netherlands, and Sinali Seafields (US). A further highlight was a plenary lecture by Steven Burrill, head of an international investor group, who underlined that biotech as a enabling technology will penetrate medicine and many areas of daily life by 2020.
“Biotechnology in Spain is currently growing at a rate of more than 25% per year” in terms of sales and exports, employment and attraction of investments, said Science and Innovation Minister Cristina Garmendia at BioSpain’s inauguration. “This is much higher than average rates in the US and the rest of Europe.” Garmendia, a former president at Genetrix, also underlined the importance of internationalisation, which she said would be paid back in exports, alliances and foreign investment.



Granada-based Integromics S.L. has teamed up with the Galician Foundation of Genomic Medicine (FPGMX) in Santiago de Compostela to secure a €1m EU grant from the European Regional Development Fund and the Spanish government. With...



Oryzon Genomics S.A (Barcelona) is entering preclinical testing with a first-in-class bispecific LSD1/MAO-B inhibitor. In addition to the classic target MAO-B, the drug also blocks histone demethylase LSD1, an epigenetic histone...



Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its...



Ordesa Laboratories has filed a patent for a novel Bifidobacterium strain isolated from infant feces. It has the capacity to combat rotavirus, says a study (Appl. Environ. Microbiol., doi:10.1128/AEM.05548).



Madrid – Researchers from Spain and the US have discovered an Ebola-like filovirus in bats in northern Spain. The first known filovirus native to Europe was reported in a study published in the journal PLOS Pathogens...



Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group...



Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and...



Madrid/Abu Dhabi – Spanish biotechs are seeking collaborations with firms in the United Arab Emirates. At the end of November, Grupo Zeltia and 14 other Spanish companies presented their research at the forum “Innovation,...



Madrid – The Spanish Minister of Innovation and Science Cristina Garmendia has responded to reports about Roche’s­ delivery stop in Greece and pessimistic expectations for Spain. In Sept­ember, she stressed that the atmosphere...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%


  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF27.6%
  • BASILEA133.60 CHF14.3%


  • CYTOS0.63 CHF-41.7%
  • MEDIGENE8.58 EUR-30.9%
  • CO.DON2.89 EUR-13.7%


  • WILEX4.20 EUR431.6%
  • FORMYCON27.70 EUR303.8%
  • 4SC4.65 EUR297.4%


  • MOLOGEN4.92 EUR-54.4%
  • BIOFRONTERA2.30 EUR-25.8%
  • CO.DON2.89 EUR-21.5%

No liability assumed, Date: 26.05.2015

Current issue

All issues